Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

167.81USD
17 Aug 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$167.81
Open
$170.69
Day's High
$171.00
Day's Low
$167.80
Volume
2,630,576
Avg. Vol
3,111,598
52-wk High
$184.21
52-wk Low
$133.64

Select another date:

Thu, Aug 17 2017

BRIEF-Amgen and Humana partner for improved health outcomes

* Amgen and Humana partner for improved health outcomes and efficiency Source text for Eikon: Further company coverage:

BRIEF-Soros Fund Management LLC dissolves share stake in Alphabet, Amgen, American Airlines ‍​

* Soros Fund Management LLC dissolves share stake in Alphabet Inc class A shares ‍​

BRIEF-Temasek Holdings takes stake in JPMorgan, Biogen, Celgene

* Temasek Holdings (Private) Ltd takes share stake in JPMorgan Chase & Co of 264,337 shares

UPDATE 1-Express Scripts to cover Mylan's EpiPen, exclude rivals

NEW YORK, July 31 Pharmacy benefit manager Express Scripts Holding Co said on Monday it would favor drugmaker Mylan Inc's versions of the EpiPen lifesaving allergy treatment over the allergy auto-injectors of other companies.

BRIEF-Amgen and Allergan submit biosimilar Biologics License application for ABP 980 to U.S. FDA

* Amgen and Allergan submit biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration

BRIEF-Amgen submits supplemental biologics license application for Prolia in glucocorticoid-induced osteoporosis

* Amgen submits supplemental biologics license application for Prolia® (denosumab) in glucocorticoid-induced osteoporosis

BRIEF-Amgen sets quarterly dividend of $1.15/shr

* Sets quarterly dividend of $1.15per share Source text for Eikon: Further company coverage:

Amgen gets fast FDA review for adding heart benefits to cholesterol drug label

Amgen Inc said on Thursday the U.S. Food and Drug Administration granted priority review to the company's request to add important heart safety data to the label of its expensive injectable cholesterol drug Repatha.

Amgen gets fast U.S. FDA review for adding heart benefits to cholesterol drug label

July 27 Amgen Inc said on Thursday the U.S. Food and Drug Administration granted priority review to the company's request to add important heart safety data to the label of its expensive injectable cholesterol drug Repatha.

BRIEF-FDA grants priority review for Amgen's supplemental biologics license application for Repatha

* FDA grants priority review for Amgen's supplemental biologics license application for Repatha® (evolocumab) to include data on reducing risk of cardiovascular events

Select another date: